This blog post is co-authored with Jennifer Roberts, Assistant Director for Health Technologies, White House Office of Science and Technology Policy, and Grail Sipes, Assistant Director for Biomedical Regulatory Policy, White House Office of Science and Technology Policy.
The COVID-19 pandemic demonstrated the need for a coordinated clinical trials enterprise, one that can swiftly characterize emerging viral threats and evaluate the effectiveness of vaccines, therapeutics, and other countermeasures across a diversity of trial participants.

Read Full Post.